Bisphosphonate drug holidays: Can we recommend currently?

Vishal R. Tandon, Sudhaa Sharma¹, Annil Mahajan²

Departments of Pharmacology, 'Obstetrics and Gynaecology and ²G Medicine, Government Medical College, Jammu and Kashmir, India.

ABSTRACT

Bisphosphonates (BP) are the mainstay of treatment for osteoporosis. Subtrochanteric or diaphyseal fractures have been reported with long term use of BP, which raised world-wide debate on two aspects, i.e., for how long the BP is to be given and potential advantages/role of BP drug holidays. BP accumulates in bone with some persistent protective effect after therapy is stopped endorses the concept. Theoretically, a drug holiday may be a considerable option to decrease risks of BP, which continuing the protection from fractures but the level of evidence and data supporting the concept of drug holidays is a week. Hence, no specific recommendations are available on BP drug holidays from major available treatment guidelines on postmenopausal osteoporosis. Hence, before it is recommended it requires more robust research in this field.

Key Words: Bisphosphonates, drug holidays, osteoporosis, postmenopausal

INTRODUCTION

Bisphosphonates (BP) are the mainstay of treatment for postmenopausal osteoporosis worldwide with established efficacy in the prevention of vertebral and nonvertebral fractures.[1-3]

They are generally well-tolerated and safe. However, there are some adverse drug reactions reported with BP such as gastrointestinal effects, acute phase reactions, musculoskeletal pain, atrial fibrillation, subtrochanteric or diaphyseal fracture, osteonecrosis of the jaw (ONJ), cutaneous hypersensitivity reactions and renal impairment.[4]

Among these, the occurrences of subtrochanteric or diaphyseal fractures has been reported with long-term use of BP but is not substantiated by epidemiologic studies or prospective randomized controlled trials. Regarding the possible mechanism of subtrochanteric or diaphyseal fractures it is unclear whether it is the effect of the drug or is due to underlying osteoporosis.[5] However, it has raised world-wide debate on two aspects, i.e., for how long the BP is to be given and potential advantages/role of BP drug holidays.

Fracture intervention trial and vertebral efficacy with risedronate therapy trials established safety and efficacy of BP for 5 years and 7 years.[6,7] The Indian Clinical Practise guidelines also recommend the use of BP for 3-5 years.[3]

Basis for the concept of bisphosphonates drug holidays

Bisphosphonates is analogs of pyrophosphate having a three-dimensional structure capable of chelating divalent cations such as Ca²⁺. The BP have a strong affinity for bone, targeting especially bone surfaces undergoing remodeling and binds strongly to hydroxyapatite and remains inactive until the bone containing BP are reabsorbed half-life after incorporation into mineralized bone nearly 10 years.[8]

Furthermore, the study of Papapoulos and Cremers, 2007[9] showed that the skeletal binding sites for BP are unsaturable and hence that they get accumulated substantially over a period of time and continues to be released for months or years after treatment is stopped.

Address for Correspondence: Dr. Sudhaa Sharma,
Department of Obstetrics and Gynaecology,
Government Medical College,
Jammu and Kashmir, India.
E-mail: annil_mahajan@rediffmail.com

Access this article online

Quick Response Code:  
Website: www.jmidlifehealth.org  
DOI: 10.4103/0976-7800.141186
Thus, it is reasonable to consider that BP accumulates in bone with some persistent protective effect after therapy is stopped. Furthermore, BP discontinuation after a long period of use has been proposed to potentially reduce the incidence of the adverse events associated with its long-term use. Thus, in view of concerns of long-term use of BP and potential advantages of its discontinuation the concept of “drug holiday” has emerged recently.

**CLINICAL TRIALS SUPPORTING THE BISPHOSPHONATES DRUG HOLIDAYS**

Vertebral efficacy with risedronate therapy trial depicted that incidence of new vertebral fractures in the year after discontinuation of 3 years of treatment was 46% lower in the former risedronate group in comparison to placebo.

Similarly, the results of Fracture Intervention Trial Long-term Extension (FLEX) trial suggested that for many women, discontinuation of alendronate for up to 5 years does not seem to significantly increase fracture risk.

In a meta-analysis by Brown et al. concluded that drug holidays should only be considered in low-risk patients and in select patients at moderate-risk of fracture after 3-5 years of therapy. Whereas, when BP are prescribed to patients at high-risk of fracture, their antifracture benefits considerably outweigh their potential for harm.

In the study of Hasegawa et al., authors supported the idea of a drug holiday. They reported that discontinuation of oral BP for 3 months might influence the incidence of BP related ONJ and wound healing after tooth extraction in patients receiving oral BP therapy.

Park-Wyllie et al. favored bisphosphonate drug holidays among older women, on treatment with a BP for more than 5 years associated with an increased risk of subtrochanteric or femoral shaft fractures.

In a study by Kostoff et al. more than one-third of postmenopausal women taking long-term BP therapy had low fracture risk, and over 40% of the patients were eligible for a drug holiday or discontinuation.

**CLINICAL TRIALS REFUTING THE BISPHOSPHONATES DRUG HOLIDAYS**

Fracture Intervention Trial Long-term Extension trial, showed that discontinuation of alendronate for up to 5 years, the anti-resorptive effect is slowly lost, mainly in the lumbar spine (about 1.5% in 5 years), as well as a slow and progressive loss of femur bone mineral density (BMD) (<3% in 5 years). Women who discontinued alendronate after 5 years showed a moderate decline in BMD and a gradual rise in biochemical markers, but no higher fracture risk other than for clinical vertebral fractures compared with those who continued alendronate. In view of these observation, the results of study recommended women at very high-risk of clinical vertebral fractures may help by continuing beyond 5 years.

The results from the FLEX compared with women who stopped alendronate after an average of 5 years, those continuing alendronate maintained a higher BMD and greater reduction of bone turnover, showing benefit of continued alendronate treatment on BMD and bone turnover. On discontinuation of alendronate therapy, rates of change in BMD at the hip and spine resumed at the background rate.

Similarly in another recent study, patients who started a BP drug holiday developed a fracture in 5.2%. Over 4 years, there was no significant change in mean lumbar spine BMD; however, there was a significant decline in the femoral neck BMD at year 2. The study further proposed that elderly patients and those with very low BMD call for close follow-up during a drug holiday. Furthermore, the study recommended that a fracture, early significant rise in bone turnover markers, and/or a decline in BMD should call for resumption of osteoporosis therapy.

Some of the other studies also provided a similar evidence that after discontinuation of alendronate after 5 years of therapy, BMD remains stable or decreases slowly while bone turnover markers stay below baseline values for up to 5 years.

Among women compliant with BPs for ≥2 years, the risk of hip fracture was increased after discontinuation, although with higher compliance and a longer duration of preceding BP therapy, this risk was attenuated. Hip fracture incidence among women who discontinued BPs versus those who did not was 8.43 versus 4.67/1000 person years (P = 0.016). The adjusted hazard ratio of hip fracture/90 days following discontinuation was 1.2 (1.1-1.3). For women with higher compliance at 2 years (MPR ≥80%) or compliant for 3 years, there were no significant differences in risk associated with discontinuation thus suggesting that discontinuation is not advisable under these conditions.

**RECOMMENDATIONS FOR BISPHOSPHONATES DRUG HOLIDAYS BY VARIOUS TREATMENT GUIDELINES ON OSTEOPOROSIS**

Major treatment guidelines worldwide and in Indian Clinical Practice guidelines on postmenopausal osteoporosis issued...
in the year 2013, no specific recommendations are made on BP drug holidays.[3]

However, American Association of Clinical Endocrinologists guidelines suggest a drug holiday after 4-5 years of BP treatment for moderate-risk patients and 10 years for high-risk patients.[22] Since there are minimal data on safe holiday durations thus, the follow-up BMD and bone turnover markers during a drug holiday period, and reinitiating therapy if bone density declines substantially, bone turnover markers increase, or fracture occurs is highly recommended under these guidelines.

American Society for Bone and Mineral Research recommended that the continued use or drug holidays of BPs beyond 5 years should be based on a re-evaluation carried annually, assessing factors such as BMD, particularly in the hip region and fracture history.[23]

McClung et al. in their studies recommended that patients on BP who are not at high-risk for fracture are potential candidates for a drug holiday and it cannot be recommended for those with BMD in the osteoporosis range or earlier history of fragility fracture. They further proposed that because the fracture probability of therapy abates slowly after stopping the treatment, while the risk of atypical fracture appears to decrease quickly, “drug holiday” of 1-2 years should be considered after 3-5 years of BP therapy except in those patients who remain at very high fracture risk.[24,25]

Diab and Watts proposed that the length of the drug holiday should be based on clinical judgment weighing risk benefit ration of discontinuation of BP therapy.[10]

### CONCLUSION

Although theoretically, a drug holiday may be considered as an option to decrease risks of BP while continuing the protection from fractures but the level of evidence and data supporting the concept of drug holidays is a week. Hence, before it is recommended even in a selective group of patients who have considerably improved on therapy in terms of BMD still it require more robust research in this field.

### REFERENCES

1. Mendoza N, Sánchez-Borrego R, Villero J, Baró F, Calaf J, Cancelo MJ, et al. 2013 Up-date of the consensus statement of the Spanish Menopause Society on postmenopausal osteoporosis. Maturitas 2013;76:99-107.

2. Kanis JA, McCloskey EV, Johansson H, Cooper C, Rizzoli R, Reginer JY, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2013;24:23-57.

3. Meeta, Harinarayan CV, Marwah R, Sahay R, Kalra S, Babhulkar S. Clinical practice guidelines on postmenopausal osteoporosis: An executive summary and recommendations. J Midlife Health 2013;4:107-26.

4. Rizzoli R, Reginer JY. Adverse drug reactions to osteoporosis treatments. Expert Rev Clin Pharmacol 2011;4:593-604.

5. Pazianas M, Cooper C, Ebetino FH, Russell RG. Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis. Ther Clin Risk Manag 2010;6:325-43.

6. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial. JAMA 1998;280:2077-82.

7. Reginer J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000;11:93-91.

8. Friedman PA. Agents affecting mineral ion homeostasis and bone turnover. In: Brunton LL, Lazo JS, Parker KL, editors. Goodman & Gilman’s the Pharmacological Basis of Therapeutics. 11th ed, Ch 16. New York: McGraw-Hill; 2006.

9. Papapoulos SE, Cremers SC. Prolonged bisphosphonate release after treatment in children. N Engl J Med 2007;356:1075-6.

10. Diab DL, Watts NB. Use of drug holidays in women taking bisphosphonates. Menopause 2014;21:195-7.

11. Ro C, Cooper O. Bisphosphonate drug holiday: Choosing appropriate candidates. Curr Osteoporos Rep 2013;11:45-51.

12. Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, et al. Effects of continuing or stopping alendronate after 5 years of treatment: The Fracture Intervention Trial Long-term Extension (FLEX): A randomized trial. JAMA 2006;296:2927-38.

13. Brown JP, Morin S, Leslie W, Papaioannou A, Cheung AM, Davison KS, et al. Bisphosphonates for treatment of osteoporosis: Expected benefits, potential harms, and drug holidays. Can Fam Physician 2014;60:324-33.

14. Hasegawa T, Ri S, Umeda M, Komatsuura H, Kobayashi M, Shigeta T, et al. The observational study of delayed wound healing after tooth extraction in patients receiving oral bisphosphonate therapy. J Cranio-maxillofac Surg 2013;41:558-63.

15. Park-Wyllie LY, Mamdani MM, Juurlink DN, Hawker GA, Gunraj N, Austin PC, et al. Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. JAMA 2011;305:783-9.

16. Kostoff MD, Saseen JJ, Borgelt LM. Evaluation of fracture risk and potential drug holidays for postmenopausal women on long-term bisphosphonate therapy. Int J Womens Health 2014;6:423-8.

17. Ensrud KE, Barrett-Connor EL, Schwartz A, Santora AC, Bauer DC, Suryawanshi S, et al. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: Results from the Fracture Intervention Trial long-term extension. J Bone Miner Res 2004;19:1259-68.

18. Chiha M, Myers LE, Ball CA, Sinacore JM, Camacho PM. Long-term follow-up of patients on drug holiday from bisphosphonates: Real-world setting. Endocr Pract 2013;19:989-94.

19. Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkay RD, Tonino RP, et al. Ten years’ experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004;350:1189-99.

20. Wasnich RD, Bagger YZ, Hosking DJ, McClung MR, Wu M, Mantz AM, et al. Changes in bone density and turnover
after alendronate or estrogen withdrawal. Menopause 2004;11:622-30.
21. Curtis JR, Westfall AO, Cheng H, Delzell E, Saag KG. Risk of hip fracture after bisphosphonate discontinuation: Implications for a drug holiday. Osteoporos Int 2008;19:1613-20.
22. Watts NB, Bilezikian JP, Camacho PM, Greenspan SL, Harris ST, Hodgson SF, et al. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis. Endocr Pract 2010;16 Suppl 3:1-37.
23. Silverman SL, Cummings SR, Watts NB, Consensus Panel of the ASBMR, ISCD, and NOF. Recommendations for the clinical evaluation of agents for treatment of osteoporosis: Consensus of an expert panel representing the American Society for Bone and Mineral Research (ASBMR), the International Society for Clinical Densitometry (ISCD), and the National Osteoporosis Foundation (NOF). J Bone Miner Res 2008;23:159-65.
24. McClung M, Harris ST, Miller PD, Bauer DC, Davison KS, Dian L, et al. Bisphosphonate therapy for osteoporosis: Benefits, risks, and drug holiday. Am J Med 2013;126:13-20.
25. McClung M. Controversies in osteoporosis management: Concerns about bisphosphonates and when are “drug holidays” required? Clin Obstet Gynecol 2013;56:743-8.

How to cite this article: Tandon VR, Sharma S, Mahajan A. Bisphosphonate drug holidays: Can we recommend currently?. J Mid-life Health 2014;5:111-4.

Source of Support: Nil, Conflict of Interest: None declared.
